NCT05037981

Completed

Effect of Early Systemic Stabilization Therapy on Recent Ons...

Cairo University Source

Compare

Other study identifiers

Sponsor study identifier

vit105

Study Type

observational

Actual enrollment (reported)

25

Locations

0 countries

Sites

N/A

Timeline

Study Start

October 10, 2015

Actual (reported)

Primary Completion

August 10, 2021

Actual (reported)

Study Completion

August 20, 2021

Actual (reported)

Brief Summary

Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most guidelines consider systemic treatments only in rapidly progressive disease with wider surface areas. This delay in halting the immune attack, may give the chance for further disease progression as well as establishment of resident memory T cell population predisposing to future disease relapses. The aim of this study was to assess the ability of early systemic therapy of localized (\<2% BSA), recent onset (\<6 months) vitiligo to control disease activity and minimize the possibility of recurrence.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 25 participants
Study completion date: August 20, 2021
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
October 10, 2015
Actual (reported)
Primary Completion
August 10, 2021
Actual (reported)
Study Completion
August 20, 2021
Actual (reported)
First Submitted
September 3, 2021
Actual (reported)
First Posted
September 8, 2021
Actual (reported)

Last Updated: September 8, 2021
Status Verified: September 2021
Last Update Submitted: September 3, 2021

Conditions

Vitiligo

Outcome Measures

Primary Outcomes (2)

Duration needed to arrest of vitiligo activity
Time needed for vitiligo patients to stop developing new lesions of vitiligo
6 months
Duration of maintaining vitiligo stability
Time before any new vitiligo lesions reappear
5 years

Eligibility Criteria

Age6 Years - 60 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

Patients with active localized vitiligo

You may qualify if:

Patients ≥ 6 years old of both genders

Sponsors & Collaborators

Cairo University
Otherlead

MeSH Terms

Conditions

Vitiligo

Condition Hierarchy (Ancestors)

HypopigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Samia Esmat, MD
Cairo University
PRINCIPAL INVESTIGATOR
Rania Mogawer, MD
Cairo University
PRINCIPAL INVESTIGATOR
Dalia Bassiony, MD
Cairo University
STUDY DIRECTOR
Suzan Shalaby, MD
Cairo University
STUDY CHAIR

Enrollment

25 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Dr

Study Record Dates

First Submitted

September 3, 2021

First Posted

September 8, 2021

Study Start

October 10, 2015

Actual (reported)

NCT03755830

Prostaglandin F2-alpha (PGF2α) in Vitiligo

Not ApplicableUnknown

NCT02281058

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

Phase 1Unknown

NCT03013049

A Novel Surgical Method in the Treatment of Unstable Vitiligo

Not ApplicableUnknown

NCT05812079

Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo

Unknown

NCT01459055

Long-term Follow-up in Patients Affected With Acrofacial Vitiligo

Unknown

NCT05706636

T Central Memory Cells in Early Localized Non-Segmental Vitiligo

Not ApplicableCompleted

Early onset vitiligo (˂6m duration)

Body surface area (BSA) affected ≤2%

You may not qualify if:

Patients who received any previous treatment for vitiligo
Pregnant and lactating females
Patients with other cutaneous or systemic autoimmune diseases
Patients with contraindication to systemic corticosteroids

Contact the study team to confirm eligibility.

Rehab Hegazy, MD

Cairo University

STUDY CHAIR

Nanis Ragab, MD

Cairo University

STUDY CHAIR

Sarah Ibrahim

Cairo University

STUDY CHAIR

Primary Completion

August 10, 2021

Actual (reported)

Study Completion

August 20, 2021

Actual (reported)

Last Updated

September 8, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05037981
Data provider: ClinicalTrials.gov
Source updated: 2021-09-08
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:46 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record